Sanitas opens new plant in Lithuania
This article was originally published in Scrip
Executive Summary
Sanitas, Lithuania's largest pharmaceutical company, has opened a new facility housing production, administration, laboratories and warehouses in an industrial district of Kaunas. The move represents a shift of its manufacturing site away from the centre of the city where its headquarters are located. The cost of the project, which started in 2005, is Lt68 million ($26.8 million) including Lt16.1 million received from EU structural funds. Sanitas said the project helped it to modernise production, increase capacity and begin making new products, such as eye drops and syringe-packed pharmaceuticals. Certification formalities are expected to be completed next month, after which the plant should start operating. It will employ 190 people and annually make up to 300 million tablets, 50 million capsules, 50 million ampoule-packed pharmaceuticals and 15 million packages each of eye drops and syringe-packed medicines.
You may also be interested in...
Poland's new law fixes prices and trade mark-ups of reimbursed drugs
Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.
Global pharma boosts business in Russia - Why Russia (introduction)
In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.
Russia's president Medvedev wants talks on trials mutual recognition with US and EU
Russia's president Dmitriy Medvedev has requested that his government start talks with the US and the EU on the mutual recognition of clinical trial results (including paediatric trials) and prepare proposals for corresponding amendments of existing regulations.